Retrospective Analysis of 4 Years of Clinical Experience with Transdermal Buprenorphine (Transtec^®) in Post-Traumatic Pain

References

• Correa GI . Dolor crónico y trauma músculo-esquelético: discapacidad e impacto económico . La revista iberoamericana del Dolor2 , 9 – 17 ( 2007 ). 
   Google Scholar
• Galvez R . Variable use of opioid pharmacotherapy for chronic noncancer pain in Europe: causes and consequences . J. Pain Palliat. Care Pharmacother.23 ( 4 ), 346 – 356 ( 2009 ). 
   PubMedGoogle Scholar
• Camba MA . Buprenorfina transdérmica en el tratamiento del dolor crónico nociceptivo . Rev. Soc. Esp. Dolor11 ( Suppl. V ), 22 – 30 ( 2004 ). 
   Google Scholar
• Gallagher AM , Leighton-ScottJ , van StaaTP . Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study . Clin. Ther.31 ( 8 ), 1707 – 1715 ( 2009 ). 
   PubMed Web of Science ®Google Scholar
• James IG , O’BrienCM , McDonaldCJ . A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain . J. Pain Symptom Manage.40 ( 2 ), 266 – 278 ( 2010 ). 
   PubMed Web of Science ®Google Scholar
• Vadivelu N , HinesRL . Management of chronic pain in the elderly: focus on transdermal buprenorphine . Clin. Interv. Aging3 ( 3 ), 421 – 430 ( 2008 ). 
   PubMed Web of Science ®Google Scholar
• Freye E , Anderson-HillemacherA , RitzdorfI , LevyJV . Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients . Pain Pract.7 ( 2 ), 123 – 129 ( 2007 ). 
   PubMedGoogle Scholar
• Gianni W , MadaioARCeciMet al. Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old . J. Pain Symptom Manage.41 ( 4 ), 707 – 714 ( 2011 ). 
   PubMed Web of Science ®Google Scholar
• Gatti A , DauriM , M LeonardisFet al. Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain . Clin. Drug Investig.30 ( Suppl. 2 ), 31 – 38 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Davis MP . Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain . J. Support. Oncol.10 ( 6 ), 209 – 219 ( 2012 ).
   PubMedGoogle Scholar
• Faymonville ME , LibbrechtD . La buprenorphine transdermique: létat actuel dans les domains clinique et pharmacologique . Rev. Med. Liege63 ( 11 ), 671 – 676 ( 2008 ). 
   PubMedGoogle Scholar
• Hans G , RobertD . Transdermal buprenorphine – a critical appraisal of its role in pain management . J. Pain Res.2 , 117 – 134 ( 2009 ).
   PubMedGoogle Scholar
• Griessinger N , SittlR , LikarR . Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients . Curr. Med. Res. Opin.21 ( 8 ), 1147 – 1156 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Likar R . KayserH , SittlR . Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials . Clin. Ther.28 ( 6 ), 943 – 952 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Schinke M . Focus on quality of life in chronic pain management: a retrospective evaluation of 133 cases treated with transdermal buprenorphine . J. Appl. Ther. Res.5 ( 4 ), 6 – 14 ( 2005 ).
   Google Scholar
• Tornero J . Buprenorfina y dolor osteomuscular. Capítulo 5 . In: Buprenorfina: un Analgésico Opioide Excepcional. Farmacología y Aplicación Clínica.BuddK , RaffaR (Eds). Ediciones Médicas SL , Barcelona, Spain , 1 – 8 ( 2005 ).
   Google Scholar
• Barutell C , CambaA , González-EscaladaJR , RodríguezM . Opioid Group of the Spanish Society for the Study of Pain. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres – a retrospective multicenter safety and efficacy study . Pain Pract.8 ( 5 ), 355 – 361 ( 2008 ).
   PubMedGoogle Scholar
• Landau CJ ,  CarrWD ,  RazzettiAJ ,  SesslerNE ,  MuneraC ,  RipaSR .  Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter. 5-week run-in and randomized, double-blind maintenance-of-analgesia study .  Clin. Ther.29 ( 10 ),  2179 – 2193  ( 2007 ).   
   PubMed Web of Science ®Google Scholar
• Miranda JP , JaqueJ , JimenezLet al. Eficacia y seguridad de buprenorfina transdérmica en manejo del dolor crónico benigno en pacientes ambulatorios de la Unidad de Dolor y Cuidados Paliativos del Hospital Clinico Universidad de Chile . Rev. El Dolor52 , 11 – 15 ( 2009 ). 
   Google Scholar
• Correa GI , CalderónW , RoaR , PiñerosJL . Buprenorfina transdérmica (Transtec®) en dolor post-traumático moderado a severo en pacientes quemados, con desforramiento o amputación de extremidades . Rev. Iberoamericana de Dolor5 , 22 – 29 ( 2010 ). 
   Google Scholar
• International Association for the Study of Pain, Subcommittee on Taxonomy. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms . Pain3 , S1–S226 ( 1986 ). 
   PubMedGoogle Scholar
• Treede RD , JensenTS , CampbellJNet al. Neuropathic pain: redefinition and a grading system for clinical and research purposes . Neurology70 ( 18 ), 1630 – 1635 ( 2008 ). 
   PubMed Web of Science ®Google Scholar
• Bouhassira D , AttalN , AlchaarHet al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) . Pain114 ( 1–2 ), 29 – 36 ( 2005 ). 
   PubMed Web of Science ®Google Scholar
• Pérez C , GalvezR , HuelbesSet al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component . Health Qual. Life Outcomes5 , 66 ( 2007 ). 
   PubMed Web of Science ®Google Scholar
• Sittl R , NuijtenM , NautrupBP . Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany . Clin. Ther.28 ( 8 ), 1144 – 1154 ( 2006 ). 
   PubMed Web of Science ®Google Scholar
• European Pharmaceutical Marketing Research Association. Anatomical Classification System. www.ephmra.org
   Google Scholar
• Change Pain Scale. www.change-pain.com/grt-change-pain-portal/GRT-CHANGE-PAIN-PORTAL_Home/Useful_Tools/Professional_Tools/Pain_Scale/154000017.jsp
   Google Scholar
• Mahoney FI , BarthelDW . Functional evaluation: the Barthel Index . Md State Med J.14 , 61 – 65 ( 1965 ). 
   PubMedGoogle Scholar
• Muriel C , CerveraJM , ConstelaMet al. Evaluación del tratamiento del dolor crónico en pacientes oncológicos con buprenorfina transdérmica . Rev. Iberoamericana del Dolor1 , 43 – 55 ( 2009 ). 
   Google Scholar
• Evans HC , EasthopeSE . Transdermal buprenorphine . Drugs63 ( 19 ), 1999 – 2010 ( 2003 ). 
   PubMed Web of Science ®Google Scholar
• Karlsson M , BerggrenAC . Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study . Clin. Ther.31 ( 3 ), 503 – 513 ( 2009 ). 
   PubMed Web of Science ®Google Scholar
• Przeklasa-Muszynska A , DobrogowskiJ . Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results form a large multicenter, non-interventional post-marketing study in Poland . Curr. Med. Res. Opin.27 ( 6 ), 1109 – 1117 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Likar R . Transdermal buprenorphine in the management of persistent pain – safety aspects . Ther. Clin. Risk Manag.2 ( 1 ), 115 – 125 ( 2006 ). 
   PubMedGoogle Scholar
• Hans G . Buprenorphine – a review of its role in neuropathic pain . J. Opioid Manag.3 ( 4 ), 195 – 206 ( 2007 ). 
   PubMedGoogle Scholar
• Kress H . Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine . Eur. J. Pain13 ( 3 ), 219 – 230 ( 2009 ). 
   PubMed Web of Science ®Google Scholar
• Pergolizzi J , AloisiAM , DahanAet al. Current knowledge of buprenorphine and its unique pharmacological profile . Pain Pract.10 ( 5 ), 428 – 450 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Pergolizzi J , BögerRH , BuddKet al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone) . Pain Pract.8 ( 4 ), 287 – 313 ( 2008 ).
   PubMedGoogle Scholar
• Wolff RF , ReidK , di NisioMet al. Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain . Pain Manage.2 ( 4 ), 351 – 362 ( 2012 ).
   PubMedGoogle Scholar
• Plosker GL . Buprenorphine 5, 10 and 20 µg/h transdermal patch: a review of its use in the management of chronic non-malignant pain . Drugs71 ( 18 ), 2491 – 2509 ( 2011 ). 
   PubMed Web of Science ®Google Scholar
• Rosenblum A , MarschLA , JosephH , PortenoyRK . Opioids and the treatment of chronic pain: controversies, current status, and future directions . Exp. Clin. Psychopharmacol.16 , 405 – 416 ( 2008 ). 
   PubMed Web of Science ®Google Scholar